Benzeneacetamide, α-[[6-(4-amino-1-piperidinyl)-3,5-dicyano-4-ethyl-2-pyridinyl]thio]- Chemical Properties

Boiling point:

669.4±55.0 °C(Predicted)

Density 

1.33±0.1 g/cm3(Predicted)

storage temp. 

Store at -20°C

solubility 

DMSO : 25 mg/mL (59.45 mM; Need ultrasonic)

form 

Solid

pka

14.65±0.50(Predicted)

color 

White to off-white

Benzeneacetamide, α-[[6-(4-amino-1-piperidinyl)-3,5-dicyano-4-ethyl-2-pyridinyl]thio]- Usage And Synthesis

Biological Activity

GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition[1]. GSK-3685032 (6 days) has cell growth inhibition of majority cancer cell lines, with a median growth IC50 value of 0.64 μM[1].GSK-3685032 (0.1-1000 nM, 1-6 days) exhibits growth inhibition after 3 days, with decreasing growth IC50 throughout a 6 d time course[1].GSK3685032 (10-10000 nM, day 4) dose-dependently increases the immune-related gene transcription[1].GSK3685032 (3.2-10,000 nM, 2 days) inhibits DNMT1 protein expression[1].GSK3685032 induces DNA hypomethylation and gene activation[1]. GSK-3685032 (1-45 mg/kg; subcutaneous twice daily for 28 days) inhibits tumor growth in the subcutaneous MV4-11 or SKM-1 xenograft models[1]. Summary of mouse pharmacokinetic parameters for GSK-3685032[1] Dose,Route Cmax(ng/mL) AUC0-8hr(h*ng/mL) DNAUC(h*kg*ng/mL/mg) Clearance(mL/min/kg) Volumedss(L/kg) T1/2(h) 2 mg/kg,IV 5103 2418 1209 13 1.3 1.8 2 mg/kg,SC 252 921 461 NA NA 2.8 2 mg/kg,SC 5473 15400 513 NA NA ND

References

[1]. Pappalardi MB, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2(10):1002-1017.

Benzeneacetamide, α-[[6-(4-amino-1-piperidinyl)-3,5-dicyano-4-ethyl-2-pyridinyl]thio]-(2170137-61-6)Related Product Information

• GSK2837808A
• GSK6853
• GSK-A1
• S)-1-(sec-butyl)-N-((4,6-diMethyl-2-oxo-1,2-dihydropyridin-3-yl)Methyl)-3-Methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxaMide
• GSK864
• GSK484
• GSK J4 HCl
• GSK 2334470
• GSK2982772
• GSK2636771
• GSK778
• N-(6-Fluoro-1H-indazol-5-yl)-2-methyl-6-oxo-4-[4-(trifluoromethyl)phenyl]-1,4,5,6-tetrahydro-3-pyridinecarboxamide
• GSK 2033
• 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl dihydrogen phosphate
• N-((S)-1-(4-((S)-2-(2,4-dichlorophenylsulfonaMido)-3-hydroxypropanoyl)piperazin-1-yl)-4-Methyl-1-oxopentan-2-yl)benzo[b]thiophene-2-carboxaMide
• GSK-2256098
• GSK215